Evrysdi (risdiplam) for oral solution, 60 mg/80mL (0.75mg/mL), 80 mL total volume after constitution, Rx only, Distributed by: Genentech, Inc. NDC:50242-175-05
Published May 5, 2021 · Recall initiated: April 20, 2021
Summary
FDA records drug Class III recall D-0357-2021, published May 5, 2021 and initiated April 20, 2021. Recalling firm: Genentech Inc; Status: Terminated; Reported quantity: 2,627 bottles; Lot: Lot #: B1001B05; B1001B08, Exp. Feb-2022. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Genentech Inc
- Distributor
- Distributed Nationwide in the USA.
- Lot
- Lot #: B1001B05; B1001B08, Exp. Feb-2022
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASusvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vialNovember 9, 2022
- FDAOxygen, Compressed, USP UN 1072, packaged in cylinders labeled as: a) M6 Medical Gas Cylinder, b) C MedicalMay 5, 2021
- FDARaley's Salt & Vinegar Flavored Potato Chips 9.5oz flexible plastic packaging 11 bags per caseMay 5, 2021
- FDATrastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vialJanuary 30, 2013
- FDANutropin AQ NuSpin 20 (somatropin (rDNA origin) injection} 20 mg/ 2mL Genentech, South San Francisco, CADecember 12, 2012
- FDANutropin AQ NuSpin 10 (somatropin (rDNA origin) injection} 10 mg/ 2mL Genentech, South San Francisco, CADecember 12, 2012
Questions about this recall
Was Evrysdi (risdiplam) for oral solution, 60 mg/80mL (0.75mg/mL), 80 mL total volume after constitution, Rx only, Distributed by: Genentech, Inc. NDC:50242-175-05 recalled?
Yes. FDA published recall D-0357-2021 on May 5, 2021. Reported hazard: Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.
What should I do if I have this product?
Voluntary: Firm initiated · Letter